Mast cell chymase: An indispensable instrument in the pathological symphony of idiopathic pulmonary fibrosis?

Histology and Histopathology

Volumn 28, Issue 6, 2013, Pages 691-699

  Kosanovic, Djuro ^a   Dahal, Bhola Kumar ^a   Wygrecka, Malgorzata ^a   Reiss, Irwin ^b   Günther, Andreas ^a   Ghofrani, Hossein Ardeschir ^a   Weissmann, Norbert ^a   Grimminger, Friedrich ^a   Seeger, Werner ^a,c   Schermuly, Ralph Theo ^a   Banat, Gamal Andre ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

Angiotensin II; Chymase; Mast cells; Pulmonary fibrosis; TGF

Indexed keywords

BIOLOGICAL MARKER; CHYMASE;

ANIMAL; DISEASE MODEL; ENZYMOLOGY; FIBROSING ALVEOLITIS; HUMAN; IMMUNOLOGY; LUNG; MAST CELL; METABOLISM; MOUSE; PATHOLOGY; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; CHYMASES; DISEASE MODELS, ANIMAL; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MAST CELLS; MICE;

ANIMALIA;

EID: 84878988452     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Abraham D.J., Vancheeswaran R., Dashwood M.R., Rajkumar V.S., Pantelides P., Xu S.W., du Bois R.M. and Black C.M. (1997). Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol. 151, 831-841.
2. Akers I.A., Parsons M., Hill M.R., Hollenberg M.D., Sanjar S., Laurent G.J. and McAnulty R.J. (2000). Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2. Am. J. Physiol. Lung Cell. Mol. Physiol. 278, L193-L201.
3. Andersson C.K., Andersson-Sjoland A., Mori M., Hallgren O., Pardo A., Eriksson L., Bjermer L., Lofdahl C.G., Selman M., Westergren-Thorsson G. and Erjefalt J.S. (2011). Activated MCTC mast cells infiltrate diseased lung areas in cystic fibrosis and idiopathic pulmonary fibrosis. Respir. Res. 12, 139.
4. Antoniades H.N., Bravo M.A., Avila R.E., Galanopoulos T., Neville-Golden J., Maxwell M. and Selman M. (1990). Platelet-derived growth factor in idiopathic pulmonary fibrosis. J. Clin. Invest. 86, 1055-1064.
5. Biernacka A., Dobaczewski M. and Frangogiannis N.G. (2011). TGFbeta signaling in fibrosis. Growth Factors 29, 196-202.
6. Cabrera S., Gaxiola M., Arreola J.L., Ramirez R., Jara P., D'Armiento J., Richards T., Selman M. and Pardo A. (2007). Overexpression of MMP9 in macrophages attenuates pulmonary fibrosis induced by bleomycin. Int. J. Biochem. Cell Biol. 39, 2324-2338.
7. Cairns J.A. and Walls A.F. (1997). Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J. Clin. Invest. 99, 1313-1321.
8. Caughey G.H., Raymond W.W. and Wolters P.J. (2000). Angiotensin II generation by mast cell alpha-and beta-chymases. Biochim. Biophys. Acta 1480, 245-257.
9. Cha S.I., Chang C.S., Kim E.K., Lee J.W., Matthay M.A., Golden J.A., Elicker B.M., Jones K., Collard H.R. and Wolters P.J. (2012). Lung mast cell density defines a subpopulation of patients with idiopathic pulmonary fibrosis. Histopathology 61, 98-106.
10. D'Orleans-Juste P., Houde M., Rae G.A., Bkaily G., Carrier E. and Simard E. (2008). Endothelin-1 (1-31): from chymase-dependent synthesis to cardiovascular pathologies. Vascul. Pharmacol. 49, 51-62.
11. Dahal B.K., Kosanovic D., Kaulen C., Cornitescu T., Savai R., Hoffmann J., Reiss I., Ghofrani H.A., Weissmann N., Kuebler W.M., Seeger W., Grimminger F. and Schermuly R.T. (2011). Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respir. Res. 12, 60.
12. Dancer R.C., Wood A.M. and Thickett D.R. (2011). Metalloproteinases in idiopathic pulmonary fibrosis. Eur. Respir. J. 38, 1461-1467.
13. De Young M.B., Nemeth E.F. and Scarpa A. (1987). Measurement of the internal pH of mast cell granules using microvolumetric fluorescence and isotopic techniques. Arch. Biochem. Biophys. 254, 222-233.
14. Doggrell S.A. and Wanstall J.C. (2004). Vascular chymase: pathophysiological role and therapeutic potential of inhibition. Cardiovasc. Res. 61, 653-662.
15. Fernandez I.E. and Eickelberg O. (2012). New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 380, 680-688.
16. Fireman E., Shahar I., Shoval S., Messer G., Dvash S. and Grief J. (2001). Morphological and biochemical properties of alveolar fibroblasts in interstitial lung diseases. Lung 179, 105-117.
17. Flechsig P., Dadrich M., Bickelhaupt S., Jenne J., Hauser K., Timke C., Peschke P., Hahn E.W., Grone H.J., Yingling J.M., Lahn M.M., Wirkner U. and Huber P.E. (2012). LY2109761 attenuates radiationinduced pulmonary murine fibrosis via reversal of TGF-beta and BMP associated proinflammatory and proangiogenic signals. Clin. Cancer Res. 18, 3616-3627.
18. Fonseca C., Abraham D. and Renzoni E.A. (2011). Endothelin in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 44, 1-10.
19. Galli S.J. and Tsai M. (2008). Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J. Dermatol. Sci. 49, 7-19.
20. Garcia-Alvarez J., Ramirez R., Sampieri C.L., Nuttall R.K., Edwards D.R., Selman M. and Pardo A. (2006). Membrane type-matrix metalloproteinases in idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffuse Lung Dis. 23, 13-21.
21. Gasse P., Mary C., Guenon I., Noulin N., Charron S., Schnyder-Candrian S., Schnyder B., Akira S., Quesniaux V.F., Lagente V., Ryffel B. and Couillin I. (2007). IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J. Clin. Invest. 117, 3786-3799.
22. Gilani S.R., Vuga L.J., Lindell K.O., Gibson K.F., Xue J., Kaminski N., Valentine V.G., Lindsay E.K., George M.P., Steele C. and Duncan S.R. (2010). CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS. One 5, e8959.
23. Gunther A., Markart P., Eickelberg O. and Seeger W. (2006). Pulmonary fibrosis-a therapeutic dilemma? Med. Klin. (Munich) 101, 308-312.
24. Hirata K., Sugama Y., Ikura Y., Ohsawa M., Inoue Y., Yamamoto S., Kitaichi M. and Ueda M. (2007). Enhanced mast cell chymase expression in human idiopathic interstitial pneumonia. Int. J. Mol. Med. 19, 565-570.
25. Horan G.S., Wood S., Ona V., Li D.J., Lukashev M.E., Weinreb P.H., Simon K.J., Hahm K., Allaire N.E., Rinaldi N.J., Goyal J., Feghali-Bostwick C.A., Matteson E.L., O'Hara C., Lafyatis R., Davis G.S., Huang X., Sheppard D. and Violette S.M. (2008). Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am. J. Respir. Crit. Care Med. 177, 56-65.
26. Hoshino T., Okamoto M., Sakazaki Y., Kato S., Young H.A. and Aizawa H. (2009). Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice. Am. J. Respir. Cell Mol. Biol. 41, 661-670.
27. Hunt L.W., Colby T.V., Weiler D.A., Sur S. and Butterfield J.H. (1992). Immunofluorescent staining for mast cells in idiopathic pulmonary fibrosis: quantification and evidence for extracellular release of mast cell tryptase. Mayo. Clin. Proc. 67, 941-948.
28. Inoue Y., King T.E. Jr, Tinkle S.S., Dockstader K. and Newman L.S. (1996). Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. Am. J. Pathol. 149, 2037-2054.
29. Izbicki G., Segel M.J., Christensen T.G., Conner M.W. and Breuer R. (2002). Time course of bleomycin-induced lung fibrosis. Int. J. Exp. Pathol. 83, 111-119.
30. Jablonska E., Markart P., Zakrzewicz D., Preissner K.T. and Wygrecka M. (2010). Transforming growth factor-'1 induces expression of human coagulation factor XII via Smad3 and JNK signaling pathways in human lung fibroblasts. J. Biol. Chem. 285, 11638-11651.
31. Khalil N. and Greenberg A.H. (1991). The role of TGF-beta in pulmonary fibrosis. Ciba. Found. Symp. 157, 194-207.
32. King T.E. Jr, Pardo A. and Selman M. (2011). Idiopathic pulmonary fibrosis. Lancet 378, 1949-1961.
33. Kitasato Y., Hoshino T., Okamoto M., Kato S., Koda Y., Nagata N., Kinoshita M., Koga H., Yoon D.Y., Asao H., Ohmoto H., Koga T., Rikimaru T. and Aizawa H. (2004). Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 31, 619-625.
34. Kofford M.W., Schwartz L.B., Schechter N.M., Yager D.R., Diegelmann R.F. and Graham M.F. (1997). Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J. Biol. Chem. 272, 7127-7131.
35. Komeda K., Jin D., Takai S., Hayashi M., Takeshita A., Shibayama Y., Tanigawa N. and Miyazaki M. (2008). Significance of chymasedependent angiotensin II formation in the progression of human liver fibrosis. Hepatol. Res. 38, 501-510.
36. Königshoff M., Wilhelm A., Jahn A., Sedding D., Amarie O.V., Eul B., Seeger W., Fink L., Gunther A., Eickelberg O. and Rose F. (2007). The angiotensin II receptor 2 is expressed and mediates angiotensin II signaling in lung fibrosis. Am. J. Respir. Cell Mol. Biol. 37, 640-650.
37. Kono M., Nakamura Y., Suda T., Kato M., Kaida Y., Hashimoto D., Inui N., Hamada E., Miyazaki O., Kurashita S., Fukamachi I., Endo K., Ng P.S., Takehara K., Nakamura H., Maekawa M. and Chida K. (2011). Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF). Clin. Chim. Acta 412, 2211-2215.
38. Kordes M., Matuschewski K. and Hafalla J.C. (2011). Caspase-1 activation of interleukin-1beta (IL-1beta) and IL-18 is dispensable for induction of experimental cerebral malaria. Infect. Immun. 79, 3633-3641.
39. Kosanovic D., Dahal B.K., Messinger J., Fischer Y., Hoffmann K., Antel J., Husen B., Hanke N., Mayet S., Ghofrani H.A., Weissmann N., Grimminger F., Seeger W. and Schermuly R.T. (2011). Pulmonary mast cell activation and increased chymase in patients with pulmonary hypertension and fibrosis. Am. J. Respir. Crit. Care Med. 183, A6427.
40. Krishnaswamy G., Kelley J., Johnson D., Youngberg G., Stone W., Huang S.K., Bieber J. and Chi D.S. (2001). The human mast cell: functions in physiology and disease. Front. Biosci. 6, D1109-D1127.
41. Lang Y.D., Chang S.F., Wang L.F. and Chen C.M. (2010). Chymase mediates paraquat-induced collagen production in human lung fibroblasts. Toxicol. Lett. 193, 19-25.
42. Lepparanta O., Sens C., Salmenkivi K., Kinnula V.L., Keski-Oja J., Myllarniemi M. and Koli K. (2012). Regulation of TGF-beta storage and activation in the human idiopathic pulmonary fibrosis lung. Cell Tissue Res. 348, 491-503.
43. Li X., Molina-Molina M., Abdul-Hafez A., Ramirez J., Serrano-Mollar A., Xaubet A. and Uhal B.D. (2006). Extravascular sources of lung angiotensin peptide synthesis in idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 291, L887-L895.
44. Markart P., Wygrecka M. and Guenther A. (2011). Update in diffuse parenchymal lung disease 2010. Am. J. Respir. Crit. Care Med. 183, 1316-1321.
45. Marshall R.P., Gohlke P., Chambers R.C., Howell D.C., Bottoms S.E., Unger T., McAnulty R.J. and Laurent G.J. (2004). Angiotensin II and the fibroproliferative response to acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 286, L156-L164.
46. Maurer M., Wedemeyer J., Metz M., Piliponsky A.M., Weller K., Chatterjea D., Clouthier D.E., Yanagisawa M.M., Tsai M. and Galli S.J. (2004). Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 432, 512-516.
47. McCormick L.L., Zhang Y., Tootell E. and Gilliam A.C. (1999). Anti-TGFbeta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J. Immunol. 163, 5693-5699.
48. McEuen A.R., Sharma B. and Walls A.F. (1995). Regulation of the activity of human chymase during storage and release from mast cells: the contributions of inorganic cations, pH, heparin and histamine. Biochim. Biophys. Acta 1267, 115-121.
49. McKeown S., Richter A.G., O'Kane C., McAuley D.F. and Thickett D.R. (2009). MMP expression and abnormal lung permeability are important determinants of outcome in IPF. Eur. Respir. J. 33, 77-84.
50. Metz M., Grimbaldeston M.A., Nakae S., Piliponsky A.M., Tsai M. and Galli S.J. (2007). Mast cells in the promotion and limitation of chronic inflammation. Immunol. Rev. 217, 304-328.
51. Miyazaki M. and Takai S. (2006a). Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J. Pharmacol. Sci. 100, 391-397.
52. Miyazaki M., Takai S., Jin D. and Muramatsu M. (2006b). Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol. Ther. 112, 668-676.
53. Mizutani H., Schechter N., Lazarus G., Black R.A. and Kupper T.S. (1991). Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J. Exp. Med. 174, 821-825.
54. Moeller A., Ask K., Warburton D., Gauldie J. and Kolb M. (2008). The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int. J. Biochem. Cell Biol. 40, 362-382.
55. Mutsaers S.E., Foster M.L., Chambers R.C., Laurent G.J. and McAnulty R.J. (1998). Increased endothelin-1 and its localization during the development of bleomycin-induced pulmonary fibrosis in rats. Am. J. Respir. Cell Mol. Biol. 18, 611-619.
56. Omoto Y., Tokime K., Yamanaka K., Habe K., Morioka T., Kurokawa I., Tsutsui H., Yamanishi K., Nakanishi K. and Mizutani H. (2006). Human mast cell chymase cleaves pro-IL-18 and generates a novel and biologically active IL-18 fragment. J. Immunol. 177, 8315-8319.
57. Oyamada S., Bianchi C., Takai S., Chu L.M. and Sellke F.W. (2011). Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion. J. Pharmacol. Exp. Ther. 339, 143-151.
58. Park S.H., Saleh D., Giaid A. and Michel R.P. (1997). Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am. J. Respir. Crit. Care Med. 156, 600-608.
59. Pejler G., Ronnberg E., Waern I. and Wernersson S. (2010). Mast cell proteases: multifaceted regulators of inflammatory disease. Blood 115, 4981-4990.
60. Pesci A., Bertorelli G., Gabrielli M. and Olivieri D. (1993). Mast cells in fibrotic lung disorders. Chest 103, 989-996.
61. Pullamsetti S.S., Savai R., Dumitrascu R., Dahal B.K., Wilhelm J., Konigshoff M., Zakrzewicz D., Ghofrani H.A., Weissmann N., Eickelberg O., Guenther A., Leiper J., Seeger W., Grimminger F. and Schermuly R.T. (2011). The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis. Sci. Transl. Med. 3, 87ra53.
62. Raghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K., Colby T.V., Cordier J.F., Flaherty K.R., Lasky J.A., Lynch D.A., Ryu J.H., Swigris J.J., Wells A.U., Ancochea J., Bouros D., Carvalho C., Costabel U., Ebina M., Hansell D.M., Johkoh T., Kim D.S., King T.E., Jr., Kondoh Y., Myers J., Müller N.L., Nicholson A.G., Richeldi L., Selman M., Dudden R.F., Griss B.S., Protzko S.L. and Schünemann H.J. (2011). An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183, 788-824.
63. Reid A.C., Silver R.B. and Levi R. (2007). Renin: at the heart of the mast cell. Immunol. Rev. 217, 123-140.
64. Reimer J.M., Enoksson M., Samollow P.B. and Hellman L. (2008). Extended substrate specificity of opossum chymase-implications for the origin of mast cell chymases. Mol. Immunol. 45, 2116-2125.
65. Ruoss S.J., Hartmann T. and Caughey G.H. (1991). Mast cell tryptase is a mitogen for cultured fibroblasts. J. Clin. Invest. 88, 493-499.
66. Sakaguchi M., Takai S., Jin D., Okamoto Y., Muramatsu M., Kim S. and Miyazaki M. (2004). A specific chymase inhibitor, NK3201, suppresses bleomycin-induced pulmonary fibrosis in hamsters. Eur. J. Pharmacol. 493, 173-176.
67. Sakamoto-Ihara T., Suzuki Y., Kurusu A., Yamashita M., Horikoshi S. and Tomino Y. (2007). Possible involvement of mast cells in renal fibrosis in patients with IgA nephropathy. Inflamm. Res. 56, 421-427.
68. Saleh D., Furukawa K., Tsao M.S., Maghazachi A., Corrin B., Yanagisawa M., Barnes P.J. and Giaid A. (1997). Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am. J. Respir. Cell Mol. Biol. 16, 187-193.
69. Sanker S., Chandrasekharan U.M., Wilk D., Glynias M.J., Karnik S.S. and Husain A. (1997). Distinct multisite synergistic interactions determine substrate specificities of human chymase and rat chymase-1 for angiotensin II formation and degradation. J. Biol. Chem. 272, 2963-2968.
70. Selman M., Ruiz V., Cabrera S., Segura L., Ramirez R., Barrios R. and Pardo A. (2000). TIMP-1,-2,-3, and-4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am. J. Physiol. Lung Cell. Mol. Physiol. 279, L562-L574.
71. Shahar I., Fireman E., Topilsky M., Grief J., Schwarz Y., Kivity S., Ben-Efraim S. and Spirer Z. (1999). Effect of endothelin-1 on alphasmooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases. Int. J. Immunopharmacol. 21, 759-775.
72. Shi-Wen X., Denton C.P., Dashwood M.R., Holmes A.M., Bou-Gharios G., Pearson J.D., Black C.M. and Abraham D.J. (2001). Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J. Invest. Dermatol. 116, 417-425.
73. Shi-Wen X., Kennedy L., Renzoni E.A., Bou-Gharios G., du Bois R.M., Black C.M., Denton C.P., Abraham D.J. and Leask A. (2007). Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum. 56, 4189-4194.
74. Simard E., Jin D., Takai S., Miyazaki M., Brochu I. and D'Orleans-Juste P. (2009). Chymase-dependent conversion of Big endothelin-1 in the mouse in vivo. J. Pharmacol. Exp. Ther. 328, 540-548.
75. Sisson T.H., Mendez M., Choi K., Subbotina N., Courey A., Cunningham A., Dave A., Engelhardt J.F., Liu X., White E.S., Thannickal V.J., Moore B.B., Christensen P.J. and Simon R.H. (2010). Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 181, 254-263.
76. Song J.W., Do K.H., Kim M.Y., Jang S.J., Colby T.V. and Kim D.S. (2009). Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest 136, 23-30.
77. Suga M., Iyonaga K., Okamoto T., Gushima Y., Miyakawa H., Akaike T. and Ando M. (2000). Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 162, 1949-1956.
78. Takai S., Jin D., Sakaguchi M., Katayama S., Muramatsu M., Sakaguchi M., Matsumura E., Kim S. and Miyazaki M. (2003). A novel chymase inhibitor, 4-[1-([bis-(4-methyl-phenyl)-methyl]-carbamoyl)3-(2-ethoxybenzyl)-4-oxo-azetidin e-2-yloxy]-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters. J. Pharmacol. Exp. Ther. 305, 17-23.
79. Takai S., Jin D., Muramatsu M., Okamoto Y. and Miyazaki M. (2004). Therapeutic applications of chymase inhibitors in cardiovascular diseases and fibrosis. Eur. J. Pharmacol. 501, 1-8.
80. Tchougounova E., Lundequist A., Fajardo I., Winberg J.O., Abrink M. and Pejler G. (2005). A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J. Biol. Chem. 280, 9291-9296.
81. Tomimori Y., Muto T., Saito K., Tanaka T., Maruoka H., Sumida M., Fukami H. and Fukuda Y. (2003). Involvement of mast cell chymase in bleomycin-induced pulmonary fibrosis in mice. Eur. J. Pharmacol. 478, 179-185.
82. Trivedi N.N. and Caughey G.H. (2010). Mast cell peptidases: chameleons of innate immunity and host defense. Am. J. Respir. Cell Mol. Biol. 42, 257-267.
83. Udalov S., Dumitrascu R., Pullamsetti S.S., Al-tamari H.M., Weissmann N., Ghofrani H.A., Guenther A., Voswinckel R., Seeger W., Grimminger F. and Schermuly R.T. (2010). Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. BMC Pulm. Med. 10, 26.
84. Uguccioni M., Pulsatelli L., Grigolo B., Facchini A., Fasano L., Cinti C., Fabbri M., Gasbarrini G. and Meliconi R. (1995). Endothelin-1 in idiopathic pulmonary fibrosis. J. Clin. Pathol. 48, 330-334.
85. Uhal B.D., Li X., Piasecki C.C. and Molina-Molina M. (2012). Angiotensin signalling in pulmonary fibrosis. Int. J. Biochem. Cell Biol. 44, 465-468.
86. Urata H., Kinoshita A., Misono K.S., Bumpus F.M. and Husain A. (1990). Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. 265, 22348-22357.
87. Wendel M., Petzold A., Koslowski R., Kasper M., Augstein A., Knels L., Bleyl J.U. and Koch T. (2004). Localization of endothelin receptors in bleomycin-induced pulmonary fibrosis in the rat. Histochem. Cell Biol. 122, 507-517.
88. Williams K., Malarkey D., Cohn L., Patrick D., Dye J. and Toews G. (2004). Identification of spontaneous feline idiopathic pulmonary fibrosis: morphology and ultrastructural evidence for a type II pneumocyte defect. Chest 125, 2278-2288.
89. Wilson M.S., Madala S.K., Ramalingam T.R., Gochuico B.R., Rosas I.O., Cheever A.W. and Wynn T.A. (2010). Bleomycin and IL-1betamediated pulmonary fibrosis is IL-17A dependent. J. Exp. Med. 207, 535-552.
90. Xu J., Mora A., Shim H., Stecenko A., Brigham K.L. and Rojas M. (2007). Role of the SDF-1/CXCR4 axis in the pathogenesis of lung injury and fibrosis. Am. J. Respir. Cell Mol. Biol. 37, 291-299.
91. Yang F., Chung A.C., Huang X.R. and Lan H.Y. (2009). Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and-independent Smad pathways: the role of Smad3. Hypertension 54, 877-884.
92. Zhang J., Gruber B.L., Marchese M.J., Zucker S., Schwartz L.B. and Kew R.R. (1999). Mast cell tryptase does not alter matrix metalloproteinase expression in human dermal fibroblasts: further evidence that proteolytically-active tryptase is a potent fibrogenic factor. J. Cell. Physiol. 181, 312-318.